Bristol Historical Financial Ratios
| BMY Stock | USD 48.30 0.46 0.96% |
Bristol Myers is presently reporting on over 114 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0374, PTB Ratio of 6.92 or Days Sales Outstanding of 130 will help investors to properly organize and evaluate Bristol Myers Squibb financial condition quickly.
Bristol |
About Bristol Financial Ratios Analysis
Bristol Myers SquibbFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Bristol Myers investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Bristol financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Bristol Myers history.
Bristol Myers Financial Ratios Chart
Bristol Myers Squibb financial ratios usually calculated using numerical values taken directly from Bristol Myers financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about Bristol Myers. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.
At this time, Bristol Myers' Free Cash Flow Per Share is fairly stable compared to the past year. Net Income Per Share is likely to rise to 4.07 in 2024, whereas Dividend Yield is likely to drop 0.04 in 2024. Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Bristol Myers Squibb stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Bristol Myers sales, a figure that is much harder to manipulate than other Bristol Myers Squibb multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Bristol Myers Squibb dividend as a percentage of Bristol Myers stock price. Bristol Myers Squibb dividend yield is a measure of Bristol Myers stock productivity, which can be interpreted as interest rate earned on an Bristol Myers investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Most ratios from Bristol Myers' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Bristol Myers Squibb current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. At this time, Bristol Myers' Free Cash Flow Per Share is fairly stable compared to the past year. Net Income Per Share is likely to rise to 4.07 in 2024, whereas Dividend Yield is likely to drop 0.04 in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Dividend Yield | 0.0317 | 0.0302 | 0.0447 | 0.0374 | Price To Sales Ratio | 2.99 | 3.32 | 2.36 | 2.98 |
Bristol Myers fundamentals Correlations
Click cells to compare fundamentals
Bristol Myers Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bristol Myers fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 4.19 | 3.29 | 2.99 | 3.32 | 2.36 | 2.98 | |
| Ptb Ratio | 2.12 | 3.7 | 3.85 | 4.93 | 3.61 | 6.92 | |
| Days Sales Outstanding | 107.29 | 72.98 | 98.49 | 110.21 | 123.79 | 129.98 | |
| Book Value Per Share | 30.26 | 16.75 | 16.18 | 14.58 | 14.22 | 14.94 | |
| Free Cash Flow Yield | 0.0588 | 0.0661 | 0.0949 | 0.11 | 0.078 | 0.13 | |
| Invested Capital | 0.92 | 1.37 | 1.27 | 1.31 | 1.41 | 1.48 | |
| Operating Cash Flow Per Share | 4.73 | 6.22 | 7.3 | 6.13 | 6.7 | 7.03 | |
| Stock Based Compensation To Revenue | 0.0169 | 0.0183 | 0.0126 | 0.009901 | 0.0115 | 0.0128 | |
| Capex To Depreciation | (0.48) | (0.0725) | (0.0911) | (0.11) | (0.12) | (0.13) | |
| Pb Ratio | 2.12 | 3.7 | 3.85 | 4.93 | 3.61 | 6.92 | |
| Ev To Sales | 5.53 | 4.17 | 3.67 | 4.0 | 3.03 | 3.11 | |
| Free Cash Flow Per Share | 4.24 | 5.89 | 6.86 | 5.61 | 6.11 | 6.42 | |
| Inventory Turnover | 1.88 | 5.68 | 4.74 | 4.33 | 4.02 | 2.54 | |
| Net Income Per Share | 2.02 | (3.98) | 3.15 | 2.97 | 3.88 | 4.07 | |
| Days Of Inventory On Hand | 193.98 | 64.3 | 76.93 | 84.22 | 90.87 | 143.64 | |
| Payables Turnover | 3.3 | 4.34 | 3.37 | 3.33 | 3.28 | 3.81 | |
| Research And Ddevelopement To Revenue | 0.31 | 0.28 | 0.24 | 0.26 | 0.21 | 0.14 | |
| Capex To Revenue | (0.032) | (0.0177) | (0.021) | (0.0242) | (0.0269) | (0.0282) | |
| Cash Per Share | 9.03 | 7.01 | 7.75 | 4.34 | 5.94 | 6.23 | |
| Pocfratio | 13.57 | 9.97 | 8.54 | 11.73 | 7.66 | 7.28 | |
| Interest Coverage | 8.33 | 3.61 | 7.62 | 8.38 | 14.79 | 20.34 | |
| Payout Ratio | 0.53 | 0.78 | (0.45) | 0.63 | 0.73 | 0.59 | |
| Capex To Operating Cash Flow | (0.1) | (0.0536) | (0.06) | (0.0856) | (0.0872) | (0.0916) | |
| Pfcf Ratio | 15.14 | 10.53 | 9.09 | 12.83 | 8.39 | 8.81 | |
| Days Payables Outstanding | 110.48 | 84.11 | 108.29 | 109.46 | 111.24 | 91.58 | |
| Income Quality | 2.33 | (1.56) | 2.31 | 2.06 | 1.72 | 1.02 | |
| Roe | 0.0666 | (0.24) | 0.19 | 0.2 | 0.27 | 0.3 | |
| Ev To Operating Cash Flow | 17.93 | 12.61 | 10.5 | 14.15 | 9.82 | 9.33 | |
| Pe Ratio | 31.82 | (15.57) | 19.8 | 24.22 | 13.23 | 19.89 | |
| Return On Tangible Assets | 0.0395 | 1.63 | 0.0791 | (0.2) | 0.16 | 0.17 | |
| Ev To Free Cash Flow | 20.0 | 13.32 | 11.17 | 15.47 | 10.76 | 11.3 | |
| Earnings Yield | 0.0583 | 0.0314 | (0.0642) | 0.0413 | 0.0756 | 0.0536 | |
| Intangibles To Total Assets | 0.67 | 0.62 | 0.58 | 0.59 | 0.51 | 0.54 | |
| Net Debt To E B I T D A | 5.33 | 2.51 | 1.57 | 1.59 | 1.56 | 1.64 | |
| Current Ratio | 5.22 | 1.6 | 1.58 | 1.25 | 1.43 | 1.96 | |
| Tangible Book Value Per Share | (20.39) | (15.9) | (12.28) | (12.39) | (9.26) | (8.8) | |
| Receivables Turnover | 3.78 | 3.4 | 5.0 | 3.71 | 3.31 | 2.95 |
Pair Trading with Bristol Myers
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.Moving together with Bristol Stock
| 0.78 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.64 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against Bristol Stock
| 0.59 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.56 | DMTK | DermTech Financial Report 2nd of May 2024 | PairCorr |
| 0.52 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.51 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.49 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Bristol Stock analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.09) | Dividend Share 2.31 | Earnings Share 3.86 | Revenue Per Share 21.753 | Quarterly Revenue Growth 0.006 |
The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.